Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
A Patterson-UTI Energy Inc. director sold 164,775 shares on March 16, 2026 for approximately $1.67 million, according to a Form 4 filing. The transaction occurred while the stock traded close to its 52-week high and followed the company's fourth-quarter 2025 results, which outperformed Street expectations and prompted higher price targets from anal…
UWM Holdings insiders Mat Ishbia and SFS Holding Corp sold a combined 2,001,148 Class A shares for roughly $7.4 million across two trading days under a 10b5-1 plan. The transactions occurred as the stock trades near its 52-week low and after the company posted a quarterly revenue beat; analysts remain divided on near-term prospects.
Exzeo Group Chief Executive Officer Paresh Patel acquired 4,000 shares of company common stock in two purchases on March 17 and March 18, 2026, totaling $63,960. The buys come while the shares trade well below their 52-week high and after Exzeo reported fourth-quarter and full-year 2025 results that met analysts’ expectations.
Koppers Holdings Inc. (NASDAQ: KOP) reported insider activity on March 17, 2026, when CEO Ball M Leroy sold 2,489 shares at $37.91 each for $94,357 and also gifted 1,200 shares the same day. The company is trading close to its 52-week high of $39.50 and has gained 39.6% year-to-date. Koppers' fourth-quarter 2025 results showed an EPS beat with $0.7…
Figma General Counsel and Secretary Brendan Mulligan sold 4,817 shares of Class A common stock on March 16, 2026, for $26.30 per share under a Rule 10b5-1 plan, netting $126,687. The transaction leaves Mulligan with 825,644 shares. The sale comes as Figma shares have fallen 76% over the past year, though the company reported robust fourth-quarter r…
Southern Copper director Luis Miguel Palomino Bonilla sold seven shares of common stock on March 12, 2026, for a total of $1,330. The transaction occurred as the stock pulled back over the prior week despite strong year-to-date gains; the company posted fourth-quarter 2025 results that beat analyst estimates while copper prices and broader miner sh…
Craig Andrew Miller, senior vice president and president of Viasat Government, sold 5,260 shares of Viasat Inc. (VSAT) stock on March 17, 2026, for $50.00 per share, totaling $263,000. The transaction occurred as the share price hovered near a 52-week high, and follows a fiscal third-quarter 2026 earnings report that beat EPS expectations but margi…
Viasat Inc. (NASDAQ: VSAT) SVP and General Counsel Robert James Blair sold 30,411 shares on March 16, 2026, realizing $1.43 million in proceeds under a Rule 10b5-1 plan. The transactions came while the stock traded near a 52-week high after a 411% gain over the past year. Separately, Viasat reported a strong fiscal third-quarter 2026 EPS result but…
Lawrence Ricketts, Executive Vice President and COO of One Liberty Properties INC (NASDAQ: OLP), sold 3,992 shares of company stock on March 16 and 17, 2026, generating proceeds of $93,031. The trades occurred as the company continued to announce industrial property acquisitions, declared its 133rd consecutive quarterly dividend, and carried a divi…
Axogen Chief Innovation Officer Erick Wayne DeVinney sold a block of shares on March 16, 2026, after exercising options and seeing restricted stock units vest. The moves included a sale to cover tax obligations tied to vesting, and occurred amid recent strong share gains and a mixed market response to the company’s fourth-quarter 2025 results.
Tarsus Pharmaceuticals director William J. Link sold 12,490 shares on March 16, 2026, generating about $859,818 across three transactions executed under a Rule 10b5-1 trading plan. The company also reported strong fourth-quarter and full-year 2025 product sales, led by XDEMVY, though its shares dipped slightly in aftermarket trading.
Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., executed an automatic insider transaction plan on March 16, 2026, exercising options to acquire 150,000 shares and selling 150,000 shares of common stock. The sale totaled $1,372,500 at a weighted average price of $9.15, while the option exercise cost $826,500. Following the act…
Agilysys INC director Melvin L. Keating bought 390 shares of common stock between March 16 and March 17, 2026, spending $27,289. The purchases were filed on a Form 4 and executed at prices between $67.98 and $68.49. The stock has traded near its 52-week low amid a 43% year-to-date decline and the company recently reported record revenue but an earn…
Root Inc.'s Chief Administrative Officer, Jonathan Allison, sold 3,990 shares of Class A common stock on March 17, 2026, for $45.00 per share under a 10b5-1 trading arrangement, realizing $179,550. The transaction leaves Allison with 85,989 directly held shares. The sale coincides with ROOT trading close to a 52-week low and follows the company's f…
Hims & Hers Health COO Michael Chi executed a sale of 97,289 Class A shares on March 17, 2026, for $24.69 per share under an existing Rule 10b5-1 plan, netting about $2.4 million. The transaction leaves Chi with 407,282 shares. The sale coincides with significant corporate developments including a collaboration with Novo Nordisk, an analyst upgrade…
Opus Genetics Chief Operating Officer Joseph K. Schachle completed an automatic sale of 3,719 shares on March 16, 2026, yielding $19,525 to satisfy tax withholding tied to restricted stock unit vesting. The disposition occurs while Opus Genetics shares trade near a 52-week high amid recent clinical progress and a $25 million capital raise.
Esperion Therapeutics President and CEO Sheldon L. Koenig sold 25,578 shares on March 17, 2026, generating $69,546 at $2.719 per share. The sale, disclosed in an SEC filing, was made to satisfy tax obligations on vested restricted stock units. Esperion reported mixed fourth-quarter 2025 results and noted regulatory guideline recognition for its cho…
Esperion Therapeutics Chief Financial Officer Benjamin Halladay sold 6,424 shares on March 17, 2026, for $2.705 per share, a transaction totaling $17,376 intended to cover tax liabilities tied to vested restricted stock units. The sale was disclosed in an SEC Form 4 filed March 18, 2026; after the trade Halladay retained direct ownership of 713,602…
Control Empresarial de Capitales S.A. de C.V., which holds roughly ten percent of PBF Energy Inc. (NYSE: PBF), sold 650,700 Class A common shares on March 16 and 17, 2026, generating about $28.8 million. The transactions occurred while the stock was trading close to its 52-week high and following PBF's fourth-quarter 2025 earnings beat, which showe…
Privia Health Group, Inc. Executive Vice President and Chief Financial Officer David Mountcastle sold 6,391 shares on March 16, 2026, to meet tax withholding obligations related to vested performance stock units. The sale, recorded on an SEC Form 4, amounted to $141,305 at a per-share price of $22.11. The transaction took place while the stock trad…
Avalo Therapeutics Inc. (NASDAQ: AVTX) Chief Medical Officer Mittie Doyle sold 25,492 common shares on March 16, 2026, for $411,606 following the exercise of options to acquire an identical number of shares. The transactions coincide with recent analyst interest and a marked year-over-year share gain, while InvestingPro data flags the stock as trad…
Opus Genetics Chief Scientific & Development Officer Jayagopal Ashwath sold 3,719 shares on March 16, 2026, to satisfy tax withholding tied to vesting restricted stock units. The transaction, executed at a weighted average price of $5.1213 per share, left Ashwath with 516,775 directly held shares. The company also reported early, favorable safety d…
Guidewire Software Inc's Chief Executive Officer, Michael George Rosenbaum, sold 4,737 shares on March 17, 2026, generating $776,194 at $163.8579 per share. The sale, disclosed as a tax-covering move tied to the settlement of Restricted Stock Units, leaves Rosenbaum with 221,206 directly held shares. The transaction comes while the stock has fallen…
K. Christopher Farkas, Executive Vice President and Chief Financial Officer of Curtiss-Wright Corporation (NYSE: CW), sold 918 shares of common stock on March 17, 2026, to satisfy tax obligations related to the vesting of restricted stock units. The transactions followed the exercise of 2,183 RSU-derived shares on March 16, 2026. Curtiss-Wright als…
Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (EXCHANGE:RCG), purchased 1,134 common shares on March 17, 2026, at $3.27 per share, a price that matches the stock's 52-week high. The total value of the transactions was $3,708. Stahl's direct stake increased to 155,654 shares, and additional shares were allocated to accounts and…
